Pharma BD Deal Intelligence

Novartis AG / AveXis Inc.

2018 · Acquisition/Merger · $8.7B · Complete

Strongly positive — critic reaction at announcement

CALLED IT — OFF BY 7

Novartis acquired AveXis for approximately $8.7 billion ($218 per share in cash), gaining the gene therapy AVXS-101 (later approved as Zolgensma/onasemnogene abeparvovec) for spinal muscular atrophy, along with a scalable gene therapy manufacturing platform and pipeline programs in Rett Syndrome and ALS.

Key facts

Announced Apr 09, 2018
Closed May 15, 2018
Deal value $8.7B
Deal type Acquisition/Merger
Therapeutic area Gene Therapy, Metabolic, Neurology, Rare Disease
Indications Spinal Muscular Atrophy Type 1, Spinal Muscular Atrophy Type 2, Rett Syndrome, SOD1-ALS
Key assets AVXS-101 (onasemnogene abeparvovec/Zolgensma), AVXS-201 (Rett Syndrome gene therapy), AVXS-301 (SOD1-ALS gene therapy), AAV gene therapy manufacturing platform
Mechanism AAV9-based gene replacement therapy targeting SMN1 gene

Related deals — scored

Deal	Year	Value	Outcome
Novartis AG / AveXis Inc. (this deal)	2018	$8.7B	68
Novartis AG / Advanced Accelerator Applications S.A.	2017	$3.9B	98
Novartis AG / Endocyte, Inc.	2018	$2.1B	96
Novartis AG / Lek Pharmaceuticals d.d.	2002	$876M	88
Novartis AG / GlaxoSmithKline plc	2014	$16.0B	81
Novartis AG / PTC Therapeutics Inc.	2024	$2.9B	80
Novartis AG / Chinook Therapeutics Inc.	2023	$3.5B	78

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2018 deals · Novartis AG deals · Gene Therapy deals